Axial: https://linktr.ee/axialxyz
Axial partners with great founders and inventors. We invest in early-stage life sciences companies such as Appia Bio, Seranova Bio, Delix Therapeutics, Simcha Therapeutics, among others often when they are no more than an idea. We are fanatical about helping the rare inventor who is compelled to build their own enduring business. If you or someone you know has a great idea or company in life sciences, Axial would be excited to get to know you and possibly invest in your vision and company. We are excited to be in business with you — email us at info@axialvc.com
Minimal residual disease (MRD) refers to the presence of residual cancer cells that remain in a patient after treatment that are undetectable by conventional methods. The detection of MRD is made possible by highly sensitive molecular techniques such as polymerase chain reaction (PCR) and next-generation sequencing (NGS) that can identify tumor-specific biomarkers and mutations in the blood or bone marrow. MRD testing has emerged as a promising tool for guiding treatment decisions and predicting outcomes in hematologic malignancies and some solid tumors.
Detecting and monitoring MRD offers several potential benefits. First, MRD status can provide an early indication of response to therapy. Patients who achieve MRD negativity after treatment have been shown to have superior outcomes compared to those with persistent MRD. Second, rising levels of MRD during or after treatment may predict impending relapse and allow for early therapeutic intervention. Additionally, MRD can be used to evaluate the depth of response to therapy and help determine optimal treatment duration. Finally, MRD testing may enable risk-stratified treatment approaches by identifying patients at highest risk of relapse who may benefit from additional therapy.
A growing body of evidence demonstrates the prognostic value of MRD in various malignancies. In acute lymphoblastic leukemia (ALL), multiple studies have shown MRD negativity is strongly associated with prolonged relapse-free and overall survival. Similar findings have been reported in acute myeloid leukemia (AML), multiple myeloma, and chronic lymphocytic leukemia. Achieving MRD negativity is now considered a crucial treatment goal in many hematologic cancers. Data also supports the prognostic value of MRD in solid tumors like breast and colon cancer.
Beyond its prognostic ability, MRD testing shows promise for guiding treatment decisions through therapy monitoring. Serial monitoring of MRD levels during and after therapy can offer an early indicator of response and allow physicians to rapidly change ineffective therapy. This “real-time” information enables greater personalization of treatment. For example, patients could be spared the toxicity of continued intense therapy if MRD levels rapidly decline. Conversely, rising MRD may prompt treatment intensification. Clinical trials evaluating such MRD-driven treatment approaches are ongoing across cancer types.
Despite its promise, several challenges must be addressed to fully validate MRD as a clinically useful biomarker. First, technical standardization is needed. Numerous assays exist to detect MRD, but methods and sensitivity vary. Lack of standardization makes comparing results across studies difficult. Internationally-accepted standards for pre-analytical variables, assay sensitivity, and data reporting would enable better validation of MRD as a biomarker. Second, clinical validation requires correlating MRD status with patient outcomes in large prospective trials across disease settings, stages, and therapies. Regulators require robust validation before accepting new surrogate endpoints like MRD. Access to banked serial biospecimens from completed trials could accelerate validation. Finally, demonstrating clinical utility, not just prognostic ability, is key for MRD adoption. Well-designed trials must show MRD testing can improve patient outcomes by guiding therapy decisions.
If successfully validated as a clinically useful biomarker, MRD assessment could transform cancer care and drug development. As a prognostic tool, MRD testing would enhance risk stratification and inform treatment decisions. As an indicator of early response to therapy, MRD could accelerate drug development by serving as a new surrogate endpoint in clinical trials. This could enable smaller, shorter trials focused on inducing MRD negativity rather than long-term survival. For patients, MRD-driven therapy adjustments could reduce over- and under-treatment.
Realizing the potential of MRD will require global collaboration across key stakeholders. Continued research should further standardize testing methodology and clinically validate MRD’s ability to improve patient outcomes. Drug developers can incorporate MRD assessment into clinical trials to generate supporting data. Regulators play a key role in establishing regulatory standards for analytical and clinical validation of MRD as a trial endpoint. Guidelines for appropriate clinical use of MRD testing are also needed. Finally, coverage and reimbursement policies will influence real-world adoption.
In summary, detecting and monitoring MRD with highly sensitive techniques represents a major advance in personalized cancer care. MRD testing provides unique biologic information to guide therapy and offers a promising new endpoint for drug development. With continued research and collaboration to enable validation, standardization, and clinical integration, MRD has transformative potential to improve outcomes for cancer patients worldwide. Critical next steps include consensus building on technical assay requirements, conducting prospective clinical utility studies, and engaging regulatory agencies to ensure appropriate evidence standards are met for this emerging biomarker.
